Bromide

Bromide

SCHEMBL7199779

Br.COc1cc(CC(C)(N)OC)ccc1Br

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HTR2A P28223 3/20 0.37
CA2 P00918 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ATM Q13315 1/20 0.37
MAPT P10636 2/20 0.36
TAAR1 Q96RJ0 3/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
HTR2C P28335 1/20 0.35
GAA P10253 1/20 0.34
LMNA P02545 1/20 0.34
GLA P06280 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27460450 0.98 CYP19A1 (0.39) CYP19A1ALDH1A1HTR2ACA2KDM4E
SCHEMBL11079829 0.83 CA2 (0.55) CYP19A1ALDH1A1CA2KDM4EATM
SCHEMBL13547950 0.82 CA2 (0.42) CYP19A1ALDH1A1HTR2ACA2KDM4E
SCHEMBL11754355 0.81 CYP19A1 (0.40) CYP19A1ALDH1A1CA2KDM4EATM
SCHEMBL18641945 0.74 KDM4E (0.48) CYP19A1ALDH1A1HTR2ACA2KDM4E
SCHEMBL13698783 0.72 PTGS2 (0.52) ALDH1A1HTR2ACA2KDM4EATM
SCHEMBL2296988 0.72 CA2 (0.47) ALDH1A1HTR2ACA2KDM4EATM
SCHEMBL29725217 0.72 CA2 (0.47) ALDH1A1HTR2ACA2KDM4EATM
SCHEMBL153912 0.71 KDM4E (0.70) CYP19A1HTR2AKDM4EATMTAAR1
SCHEMBL2295220 0.71 HSD17B10 (0.47) ALDH1A1HTR2ACA2MAPTTAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030050226-A1 Dopamine analog amide SHASHOUA VICTOR E (US) 2003-03-13 US disclosed
US-6407137-B2 A PRODRUG COMPOUND CAPABLE OF FACILITATING THE PASSAGE OF A DRUG ACROSS THE BLOOD BRAIN BARRIER COMPRISING A FATTY ACID COUPLED TO A DRUG TO FORM A PRODRUG PROTARGA, INC. 2002-06-18 US disclosed
US-20010056116-A1 Dopamine analog amide LUITPOLD PHARMACEUTICALS, INC. 2001-12-27 US disclosed
US-6258836-B1 FATTY ACID COUPLED TO ANTIAIDS SUBSTANCE, ANTIBIOTIC, CHOLINERGIC AGONIST AND OTHER USES FOR PASSING THE BLOOD BRAIN BARRIER PROTARGA, INC. 2001-07-10 US disclosed
US-6107499-A FACILITATING THE TRANSPORT OF A NEUROTRANSMITTER ACROSS THE BLOOD BRAIN BARRIER BY ADMINISTERING THE DRUG, A NEUROTRANSMITTER SUCH AS DOPAMINE COVALENTLY COUPLED TO A SINGLE, STRAIGHT-CHAINED FATTY ACID CARRIER MOLECULE NEUROMEDICA, INC. (US) 2000-08-22 US disclosed
US-5994392-A PASSAGE OF DRUG THROUGH BLOOD BRAIN BARRIER NEUROMEDICA, INC. (US) 1999-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010056116-A1 Dopamine analog amide FABP7, SLC6A3, ALOX15 CYP19A1 379/4885ALDH1A1 134/4885HTR2A 20/4885
US-20030050226-A1 Dopamine analog amide FABP7, SLC6A3, ALOX15 CYP19A1 379/4885ALDH1A1 134/4885HTR2A 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.